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Abstract
Background: Systematic reviews have shown uncertainty about the size or direction of any ‘trial effect’ for patients
in trials compared to those treated outside trials. We are not aware of any systematic review of whether there is a
‘trial effect’ related to being treated by healthcare practitioners or institutions that take part in research.
Methods: We searched the Cochrane Methodology Register and MEDLINE (most recently in January 2009) for
studies in which patients were allocated to treatment in one or other setting, and cohort studies reporting the
outcomes of patients from different settings. We independently assessed study quality, including the control of
bias in the generation of the comparison groups, and extracted data.
Results: We retrieved and checked more than 15,000 records. Thirteen articles were eligible: five practitioner
studies and eight institution studies. Meta-analyses were not possible because of heterogeneity. Two practitioner
studies were judged to be ‘controlled’ or better. A Canadian study among nurses found that use of research
evidence was higher for those who took part in research working groups and a Danish study on general
practitioners found that trial doctors were more likely to prescribe in accordance with research evidence and
guidelines. Five institution studies were ‘controlled’ but provided mixed results. A study of North American patients
at hospitals that had taken part in trials for myocardial infarction found no statistically significant difference in
treatment for patients in trial and non-trial hospitals. A Canadian study of myocardial infarction patients found that
trial participants had better survival than patients in the same hospitals who were not in trials or those in non-trial
hospitals. A study of general practices in Denmark did not detect differences in guideline adherence between trial
and non-trial practices but found that trial practices were more likely to prescribe the trial sponsor’s drugs. The
other two ‘controlled’ studies of institutions found lower mortality in trial than non-trial hospitals.
Conclusions: The available findings from existing research suggest that there might be a ‘trial effect’ of better
outcomes, greater adherence to guidelines and more use of evidence by practitioners and institutions that take
part in trials. However, the consequences for patient health are uncertain and the most robust conclusion may be
that there is no apparent evidence that patients treated by practitioners or in institutions that take part in trials do
worse than those treated elsewhere.
Background
The involvement of increasing numbers of patients in
clinical research, in particular randomised trials, is
necessary to resolve uncertainties about healthcare inter-
ventions. A Cochrane methodology review has brought
together evidence comparing the outcomes of patients
treated in randomised trials with similar patients who
received similar treatments outside trials [1]. It found
continuing uncertainty about the size or direction of any
‘trial effect’ for patients in trials but, in general, partici-
pation in trials was not associated with any obvious ben-
efit or harm.
We report here a systematic review of whether there is a
trial effect at the level of healthcare practitioners or insti-
tutions. We set out to answer the question: do patients
who are treated by practitioners or in institutions that take
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elsewhere? The answer to this question is important to
patients who might wish to use the evidence when making
a choice about where they receive their health care and
from whom, or who wish to use it as a guide to the quality
of care they will receive. It is also important that policy
makers and others involved in decisions about practi-
tioners and institutions have access to evidence on possi-
ble relationships between the participation in research of
practitioners or institutions and the outcomes of their
non-trial patients. We examined this with research that
has looked at health outcomes for patients, the uptake of
evidence from research, and adherence to practice guide-
lines. A systematic review is necessary to avoid undue
emphasis on the findings of individual studies, which may
have found beneficial or harmful effects. This review was
commissioned by the National Institute for Health
Research, including an assessment of the effects on
patients of their own participation in clinical trials, supple-
menting the work of Vist et al [1], but that is not reported
here as it confirmed their findings.
We sought to assess patient related outcomes in the
following situations: (1) patients treated by healthcare
practitioners who take part in clinical trials versus simi-
lar practitioners who do not take part; and (2) patients
treated in institutions that take part in clinical trials ver-
sus those treated in similar institutions that do not take
part in such trials. In doing this, we recognised that
there is a possibility of clustering due to the association
between the practitioner and the institution (i.e. would
any effect detected be due to the practitioner or to the
institution within which they work?). We tried to com-
pensate for this by placing most emphasis on studies in
which there was a mixture of research and non-research
practitioners in an institution. We also sought to distin-
guish between the outcomes for patients being treated
in trials, with those being treated outside of trials by the
research practitioners or institutions; and to assess
the extent to which the studies we identified dealt with
the confounding that might arise if the patients being
treated by research practitioners or in research institu-
tions are fundamentally different to the patients in non-
researching settings.
Methods
We conducted the review in accordance with the meth-
ods used within The Cochrane Collaboration for
systematic reviews of methodology [2].
Eligibility criteria of studies
Types of study
Studies that reported empirical comparisons of the dif-
ferent situations were eligible if patients were rando-
mised or allocated by other means to treatment by
research versus non-research practitioners, or to treat-
ment in a research versus a non-research institution.,
Cohort studies in which the outcomes of patients trea-
ted by research versus non-research practitioners, or in
a research versus a non-research institution, or both
were also eligible. We did not generate our own com-
parisons between groups of patients through, for exam-
ple, comparing independent reports of patients treated
in institutions that took part in trials and other reports
of patients treated in non-trial institutions. All types of
institution providing health care, all types of healthcare
practitioner, and all types of patient (including people
who were healthy and, for example receiving interven-
tions to prevent illness) were eligible.
Types of outcome measure
The primary outcome measure was the health of
patients, as reported in each included study. In recogni-
tion of the fact that such outcomes may be poorly
reported and may be subject to confounding that is dif-
ficult to correct for (for example, because of variations
in the referral patterns for hospitals that take part in
research and those that do not), secondary outcomes
included the uptake of the findings of research and
adherence to practice guidelines.
Search methods for identification of studies
Searching for studies of relevance to reviews similar to
this has been noted to be especially difficult, not least
because of the absence of suitable search terms within
medical literature databases [3,4]. Therefore, we began
our searches with the Cochrane Methodology Register,
which has been compiled as a resource for articles rele-
vant to the methodology of evaluations of health and
social care [5]. It contained more than 11,000 biblio-
graphic records, as of January 2009. We searched the
version of the Register from Issue 1, 2009 of The
Cochrane Library. Records in the Register are assigned
index terms from a taxonomy that is maintained by the
Cochrane Methodology Review Group. We retrieved all
records with the following index terms: ‘Applicability
and recommendations - Assessments of the impact of
research’, ‘Applicability and recommendations - Levels
of evidence and strength of recommendations’, ‘Applic-
ability and recommendations - Recommendations’,
‘Consumer involvement’, ‘Eligible and randomised versus
eligible and not randomised’ and ‘Patient involvement’.
Two researchers (TC and MC) checked each record
independently to identify reports that might be eligible
for the review. The records identified as eligible or poten-
tially eligible from the Cochrane Methodology Register
were used as the ‘seeds’ for related articles searches
in PubMed. These searches were done in December
2008. The records for 3964 related articles were checked
independently by two researchers (TC and MC). Finally,
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MEDLINE (Additional File 1). This search was run on 23
January 2009 using OvidSP MEDLINE, for the period
from 1950 to mid-January 2009, with no language or
publication year restrictions. All 9820 retrieved records
were checked independently by two researchers (TC and
MC). The references in the reports of included studies
were also checked for relevance by KL and MC. Full text
copies of potentially eligible articles were obtained, and
checked by one of two researchers (KL or MC), who then
discussed and agreed on the eligibility of each study.
Although searches of other databases or sources might
have revealed further studies, the restriction to the
Cochrane Methodology Register and MEDLINE was
influenced by the comprehensive nature of the processes
that have been used to compile the former and the
resources available for this review.
Data extraction and analyses
The following information was extracted for each study:
reference; population and setting or interventions stu-
died (including details on the practitioners and institu-
tions, if appropriate); means used to establish the trial
group and the comparator group; confounders and how
these were adjusted for (including different diagnoses of
patients or different treatments); outcomes (including
patient health, use of evidence from trials or guidelines);
and a summary of the relevant results. These data were
extracted by one researcher (KL) and checked by a sec-
ond (MC).
The risk of bias in each study was assessed by consid-
ering the control of selection bias in the groups being
compared. We judged a study to be ‘well controlled’ if it
used random allocation to allocate patients to be treated
by practitioners who do take part in trials versus practi-
tioners who do not take part in trials, or in institutions
that do take part in trials versus institutions that do not
take part. Studies were categorised as ‘controlled’ if ran-
dom allocation was not used but attempts were made to
control for all confounding factors or if it was reported
that the study contained no imbalances in confounding
factors. Studies that reported imbalances in confounding
factors and did not attempt to control for these in the
analyses were categorised as ‘poorly controlled’.T h e s e
categories are similar to those used in the Cochrane
methodology review investigating the possibility of a
trial effect in patients in research studies [1].
Results
Overall
The searches identified a total of 15,149 records. Follow-
ing our independent screening of these and the checking
of reference lists, we identified 21 potentially eligible
studies for practitioners, 17 for institutions, and 10 that
were initially unclassified. Full copies of the articles
were obtained and checked against the eligibility criteria,
leading to a total of 13 articles for this review. There
were 5 articles for the review of practitioners and 8 arti-
cles for the review of institutions. The included studies
are summarised in Table 1. We were unable to do a
meaningful meta-analysis within any of the categories
because of heterogeneity across the individual studies,
and the lack of a significant difference in a study should
not be taken as evidence that there truly is no difference
since the studies were not necessarily adequately pow-
ered to detect a difference should there be one, in either
direction.
Practitioners
We identified five studies comparing patient-care related
outcomes for practitioners who took part in clinical
research versus outcomes for practitioners who had not
taken part in clinical research [6-10]. The studies were
heterogeneous and their findings are presented individu-
ally, with no meta-analyses. Two trials were judged to
be ‘controlled’ or better [6,7] and these are described
first in this section.
Meineche-Schmidt et al reported a study called
ONETWO which investigated the impact of taking part
in a randomised trial (ONE) of ‘on demand’ versus
treatment courses for the management of gastro-
oesophageal reflux disease. They compared prescribing
patterns among 64 general practitioners (GPs) who took
part versus a random sample of 58 other Danish GPs
[6]. The study compared the outcomes of 247 patients
treated by the GPs within ONE, 451 similar patients
treated by the same GPs outside ONE, and 469 similar
patients treated by the comparator GPs outside of ONE.
GPs who took part in the trial were significantly more
likely to prescribe ‘on demand’ proton-pump inhibitors
to their patients (322 of 698, 47%) than was the case for
other GPs (129 of 469, 27%) (P < 0.0001). We judged
this study to be ‘controlled’ because there were few
baseline imbalances between the trial and non-trial GPs
(on sex, geography, number of years as doctors and dis-
t r i b u t i o nb yr e g i o no rt y p eo fp r a c t i c e )o rb e t w e e nt h e i r
patients (on age and sex, but symptoms were signifi-
cantly lower at baseline in the trial patients), and the
means for establishing the control group was unlikely to
introduce major bias.
Tranmer et al conducted a randomised trial in a
teaching hospital in Canada in which nurses in two
medical surgical units were allocated to a high level of
participation in research, nurses in two other units were
randomised to a low level of participation and nurses in
the final two units were randomised to no participation
[7]. After randomisation, nurses in the high- and low-
participation units were invited to join the relevant
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Reference Type of participants Intervention Outcome measures Brief summary
Practitioners
6 General Practitioners in Denmark Treatment for gastro-oesophageal
reflux disease
Drug prescription for
individual patients
GPs who took part in trial
significantly more likely to
prescribe ‘trial drug’ proton
pump inhibitors than other GPs.
7 Nurses in Canadian teaching
hospital
Research working groups Nurses attitudes to research,
access to research, support of
the use of research, use of
research
Post intervention scores were
higher for nurses involved in
high or low research
participation units than for
nurses in the units that did not
take part in these groups.
8 Gastrointestinal specialists Management of Barrett’s
oesophagus
Adherence to international
guidelines, especially in regard
to tissue sampling
Adherence to guidelines
increased after the trial started,
particularly in trial centres.
8 Hospital doctors Treatment for myocardial
infarction
Medication received on
discharge compared to
admission
Doctors involved in trials change
prescribing practice quicker than
physicians in routine practice.
10 Surgeons in 3 adjacent counties
in England
Discharge decisions following
inguinal hernia and varicose veins
surgery
Mean length of hospital stay The mean length of stay
decreased significantly in the
trial area, with less effect in
control areas.
Institutions
11 Trial (high and low participation)
and non-trial hospitals in
CRUSADE (Can Rapid
Stratification of Unstable Angina
Patients Suppress Outcomes With
Early Implementation of the
American College of Cardiology/
American Heart Association
Guidelines), North America
Treatment for patients with high-
risk non-ST-segment elevation
acute coronary syndrome with
unstable angina and non-ST
segment elevation acute coronary
syndrome
All cause mortality and
adherence to guidelines
In-hospital mortality was lower
in high trial participation
hospitals compared to low
participation and non-trial
hospitals.
Greater adherence to guidelines
in high trial participation
hospitals compared to low
participation and non-trial
hospitals.
12 Acute care hospitals in Ontario,
Canada participating in trials and
those not.
Treatment for myocardial
infarction
Hospital mortality and
treatment information
Patients in trial hospitals fared
better than patients in non-trial
hospitals
13 Gynaecological departments in
hospitals in Germany taking part
in clinical trials and hospitals not
taking part
Treatment for ovarian cancer Survival from diagnosis to
date of last follow up or
death for up to two years
after diagnosis and adherence
to treatment guidelines.
Treatment in hospitals that did
not participate in trials was
associated with significant risk of
death (adjusted for differences in
stage of patients)
14 General practitioners in trial and
non-trial practices in Denmark
Management of asthma Physicians’ adherence to
international treatment
recommendations and use of
trial sponsors drugs
No change in adherence to
guidelines in trial practices but
there was an increase in
prescription of sponsor drugs in
trial practices
15 Hospitals in North America
involved in the Survival and
Ventricular Enlargement trial
(SAVE) and in the Multicenter
Diltiazem Postinfarction Trial
(MDPIT) and hospitals not
involved in these trials.
Treatment for myocardial
infarction
Prescribing of angiotensin-
converting inhibitors (ACE) at
hospital discharge
No significant differences
between trial and non-trial
hospitals.
16 Cancer care facilities: community
hospital, community cancer
centre and teaching/research
facilities in the USA
Treatment of patients with
advanced stage laryngeal cancer
Chemotherapy and radiation
treatment to patients
Higher percentage of patients
with advanced-stage laryngeal
cancer were treated with
chemo-radiation in teaching/
research hospitals than in
community hospitals and
community cancer centres
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respectively, volunteered. Information on the use of
research was sought through a self-reported question-
naire before the intervention and one year after from a
total sample of 190 nurses. It was found to increase in
all units, with no significant differences between the
three types of unit. The post intervention scores were
higher for nurses who took part in the research working
groups in the high- and low-participation units than the
nurses that did not take part in these groups. We judged
this study to be ‘well controlled’ because of the use of
randomisation to create the different levels of exposure
to research. However, the sample size was small and
cluster randomisation was used, with only two medical
surgical units in each of the three interventions.
The three other studies were judged to be ‘poorly con-
trolled’ because of the possibility of differences between
the patients seen by trial and non-trial practitioners [8],
or because health outcomes between these two groups
of patients might have been influenced by the use of dif-
ferent treatments for them [9], or both [10].
Das et al compared practice in the UK centre that
recruited most patients to a randomised chemopreven-
tion trial, the Aspirin Esomeprazole Chemoprevention
Trial (AspECT), before and after the start of the trial
[8]. They audited biopsies to compare AspECT patients
with non-AspECT patients in these two periods. They
found no statistically significant difference between
AspECT and non-AspECT groups while AspECT was
ongoing. However, both these patient groups had signifi-
cantly more biopsies per cm length of Barrett’s oesopha-
gus compared to similar patients treated before
AspECT. We judged this study to be ‘poorly controlled’
because the report does not mention (or appear to con-
trol for) changes over time, which might have influenced
the change in the number of biopsies independently of
involvement in the randomised trial. Such changes
might have occurred because of, for example, changes in
other treatments or in routine practice.
Kizer et al investigated the uptake of the findings of
randomised trials and recommendations from guidelines
during 1978 to 1995 for patients needing treatment for
the secondary prevention of myocardial infarction who
were enrolled in the Multicenter Investigation on Lim-
itation of Infarct Size (MILIS) and Thrombolysis in
Myocardial Infarction (TIMI) trials [9]. They compared
medication use by non-trial and trial physicians using
data on medication use at enrolment as the guide
to decision making by non-trial physicians and data at
discharge as the guide to decision making by trial practi-
tioners. Effective drugs (aspirin, beta-blockers, angioten-
sin-converting enzyme (ACE) inhibitors) tended to be
more common at discharge than at enrolment. The
reverse was true for an ineffective class of drugs (cal-
cium channel blockers). The authors concluded that
they had demonstrated ‘prompt responses by physicians
who design or implement randomized clinical trials to
the results of RCTs and study overviews’ which they
contrast with ‘enduring deficiencies in the application of
RCT results by physicians in routine practice, despite
publication of synthesizing overviews and task force
guidelines.’ We judged this study to be ‘poorly con-
trolled’ because the report does not adjust for differ-
ences over time in patient characteristics which might
have influenced the prescription or use of the medica-
tions investigated.
Adler examined the discharge decisions of surgeons
in three adjacent areas of England. A randomised trial
had taken place in one of these areas [10]. The com-
parison was made for 1970 and 1975, studying the
impact of the 1973 release of the preliminary results of
the randomised trial, which favoured early discharge
following inguinal hernia and varicose veins surgery.
Large changes were seen in the study area but not in
the adjacent, control health districts. The mean length
of stay decreased significantly in the trial area and
there was less effect in the control areas. The author
concluded ‘the research findings played a part in chan-
ging clinical practice in the study area’. We judged the
study to be ‘poorly controlled’ because no information
was presented on why the control areas were chosen
(in preference to other areas adjacent to the area of
the trial) and the analyses did not adjust for potential
confounders, such as the types of patient in the differ-
ent areas or the types of treatment provided in the dif-
ferent areas.
Table 1 Summary of included studies (Continued)
17 Apheresis units in major medical
centres in Canada
Treatment of multiple sclerosis,
thrombotic thrombocytopenic
purpura, and myeloma cast
nephropathy
Apheresis Large increase in apheresis use,
particularly outside trials, labelled
‘jumping the gun’ by the
research team.
18 Centres taking part in ADEBAR
trial of chemotherapy for women
with breast cancer
Treatment for breast cancer Changes to treatment
strategies and patient care
since participating in ADEBAR
Prior to ADEBAR, 63.2% of
centres had not entered high-
risk breast cancer patients into a
clinical trial and 44.2% of
patients received inadequate
treatment by current standards.
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We identified seven studies (four of which we judged to
be ‘controlled’) which compared patient-care related
outcomes for institutions that had taken part in clinical
research versus outcomes for institutions that had not
taken part in clinical research [11-17]. and one study
which compared the uptake of a trial’s results by institu-
tions that had and had not taken part in it [11]. We
were unable to do a meaningful meta-analysis because
of heterogeneity across the individual studies and there-
fore present the results of each study separately, begin-
ning with the five studies judged to be ‘controlled’
[11-15]. The first of these is the study of the uptake of a
trial’s results by participating and non-participating
hospitals.
Majumdar et al investigated the impact on practice of
being part of a myocardial infarction trial that showed a
treatment (ACE inhibitors) to be beneficial and of
another trial that showed a treatment (calcium channel
blockers) to be ineffective; in hospitals that were taking
part in a third randomised trial, GUSTO-1, in North
America [11]. They compared the 22 hospitals that took
part in the Survival and Ventricular Enlargement
(SAVE) trial from 1987 to 1990 with hospitals that did
not take part in it; and the nine hospitals that took part
in the Multicenter Diltiazem Post-Infarction Trial
(MDPIT) with those that did not. There was no statisti-
cally significant difference in the percentage of patients
who received an ACE inhibitor at discharge in hospitals
that had taken part in SAVE compared to non-SAVE
hospitals. The adjusted odds ratio was 1.1 (95% CI 0.8
to 1.4, P = 0.67). There was no statistically significant
difference in the percentage of patients who received a
calcium channel blocker at discharge in hospitals that
had taken part in MDPIT compared to non-MDPIT
hospitals (adjusted OR 0.8, 95% CI 0.5 to 1.3, P = 0.58).
We judged this study to be ‘controlled’ because potential
confounders were adjusted for in the analyses and the
analyses also accounted for statistical clustering of
patients treated at the same hospital.
From 1989 to 1993, Jha et al studied five groups of
acute myocardial infarction patients in Ontario, Canada
using data on hospital admissions [12]. Four of these
groups were participants and non-participants in hospi-
tals taking part in each of two thrombolysis studies:
GUSTO (Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries)
and LATE (Late Assessment of Thrombolytic Efficacy).
The fifth group consisted of patients from other hospi-
tals not participating in these trials. There were
30 GUSTO hospitals, 10 LATE hospitals and 165 exter-
nal hospitals. Hospital mortality was higher at the non-
trial hospitals (17.4%) than it was for trial participants
(GUSTO: 6.9%; LATE: 6.6%) at the trial hospitals but
similar to that for non-participants in those hospitals
(GUSTO: 16.8%; LATE: 19.7%). After adjustment for
patient characteristics, survival in the trial hospitals was
higher among participants than non-participants
(GUSTO: odds ratio 1.8, 95% CI 1.4 to 2.2; LATE: OR
2.1, 95% CI 1.2 to 3.6), and it was higher among trial
participants than non-trial patients in external hospitals
(GUSTO: OR 1.8, 95% CI 1.5 to 2.4; LATE: OR 1.8, 95%
CI 1.0 to 3.2). However, survival for non-trial patients at
GUSTO hospitals was similar to that for patients at
external hospitals (OR 1.0 95% CI 0.9 to 1.1), and it was
lower for non-trial patients at LATE hospitals (OR 0.8
95% CI 0.8 to 1.0) compared to patients at external hos-
pitals. We judged this study to be ‘controlled’ because
analyses were adjusted for potential confounders.
A study of gynaecological departments in 165 German
hospitals sought data on the treatment and two year sur-
vival of ovarian cancer patients diagnosed in the third
quarter of 2001 [13]. Eighty of these hospitals were
involved in clinical trials conducted by one of two co-
operative groups in Germany: the Ovarian Cancer Study
Group and the Northeastern Society of Gynaecologic
Oncology, and 85 hospitals were not participating in
these trials. Treatment in a non-trial hospital was asso-
ciated with a significantly increased risk of death (hazard
ratio 1.82, 95% CI 1.27 to 2.61, P = 0.001) after adjust-
ment for baseline factors. Measures of adherence to
treatment guidelines also favoured patients treated in
study hospitals. We judged this study to be ‘controlled’
because analyses were adjusted for potential confounders.
Andersen et al investigated adherence to asthma
guidelines and use of drugs manufactured by the trial’s
sponsor, in relation to the participation of general prac-
tices in a trial [14]. Ten practices taking part in the trial
(SymbiAC) of an asthma treatment were compared with
165 non-trial control practices in Denmark in the early
2000s. There was no significant effect of trial participa-
tion on guideline adherence comparing the second year
after participation in the trial with the year before parti-
cipation (odds ratio for the second year for trial versus
non trial practices: 1.00, 95% CI 0.84 to 1.19). Prescrib-
ing of the trial sponsor’s drug rose from 17.4% to 55.4%
in trial practices, and from 14.8% to 40.5% in non-trial
practices (not significantly different between trial and
non-trial practices). However, the sponsoring company’s
share of the total prescribing volume of asthma drugs
increased significantly more in trial practices than in
non-trial practices (OR 1.26, 95% CI 1.04 to 1.54). The
authors concluded that their study was not able to
detect reliably any impact on guideline adherence but
that their study ‘confirms the hypothesis that physician
involvement in clinical trials is a powerful tool for influ-
encing company-specific drug preferences’.W ej u d g e d
this study to be ‘controlled’ because the analyses
Clarke and Loudon Trials 2011, 12:16
http://www.trialsjournal.com/content/12/1/16
Page 6 of 10adjusted for baseline imbalances between the practices.
Furthermore, the choice of control practices is unlikely
to introduce major bias, because it included almost all
of the practices in the same region as the trial practices.
For the period 2001 to 2006, Majumdar et al com-
pared US hospitals that had no trial participation (145
hospitals), low trial participation (226 hospitals, median
1% of patients enrolled in trials) and high trial participa-
tion (123 hospitals, median 4.9% of patients enrolled in
trials) on hospital mortality and adherence to guidelines
for 174,062 patients with high-risk non-ST-segment ele-
vation acute coronary syndrome [15]. Patients treated at
hospitals that participated in trials had significantly
lower mortality than patients treated at non-participat-
ing hospitals: 5.9% for non-trial hospitals, 4.4% for low-
participation hospitals and 3.5% for high-participation
hospitals (adjusted P-valuef o rt r e n d0 . 0 0 3 ) .T h ec o m -
parison of low-participation hospitals versus non-trial
hospitals produced an adjusted odds ratio of 0.9 (95%
CI 0.8 to 1.0, P = 0.04) and the comparison of high-
participation hospitals versus non-trial hospitals pro-
duced an adjusted odds ratio of 0.8 (95% CI 0.7 to 0.9,
P = 0.003). A composite guideline adherence score was
also used to assess the uptake of nine recommendations
from guidelines. This increased with increasing trial par-
ticipation: 76.9% versus 78.3% versus 81.1% for non-
trial, low-participation and high-participation hospitals,
respectively (adjusted P-value for trend 0.008). We
judged this study to be ‘controlled’ because analyses
were adjusted for potential confounders. This was done
for hospital and patient characteristics for the hospital
mortality analyses and for hospital characteristics for the
analyses of guidelines adherence.
The three other studies of the possibility of a trial
effect for institutions were judged to be ‘poorly con-
trolled’ because of the possibility of differences between
the patients in the different institutions [16-18].
Three types of American institutions involved in the
care of patients with cancer were studied from 1985 to
2001 by Chen et al: community hospitals, community
cancer centres and teaching/research facilities [16]. The
impact of the 1991 publication of a randomised trial
demonstrating similar survival between non-surgical
therapy (chemo-radiotherapy) and total laryngectomy
for patients with advanced laryngeal cancer was investi-
gated. Over the whole period, patients in teaching/
research facilities were more likely to be treated with
chemo-radiotherapy (14.2%), compared with community
hospitals (12.9%) and community cancer centres
(13.1%). The percentage of patients with advanced laryn-
geal cancer treated with chemo-radiotherapy increased
overtime in all centres but use of chemo-radiotherapy
increased at a significantly faster rate in community can-
cer centres and teaching/research facilities after the
publication of the VA Laryngeal Cancer Study. We
judged this study to be ‘poorly controlled’ because dif-
ferences in the demographic and clinical characteristics
of the patients at the different types of institution do
not appear to have been accounted for in the analyses.
Clark et al studied data on apheresis use in 19 units
taking part in a randomised trial of apheresis for mye-
loma cast nephropathy and five non-trial units (1998 to
2000) [17]. They found increased use of apheresis in
both types of institution. In trial centres, the number of
patients undergoing apheresis increased from 62 to 127
per year (with 35 of the 127 being patients in the trial).
In non-trial centres, the annual number increased from
71 to 88. We judged this study to be ‘poorly controlled’
because there was no discussion of potential confound-
ing variables between the trial and non-trial centres,
such as those relating to the case mix of patients which
might have arisen due to different referral patterns.
Centres taking part in the German ADEBAR rando-
mised trial of chemotherapy regimens for women with
high-risk breast cancer were studied by Janni et al,
before and after they recruited patients to the trial [18].
The study period ran from 2001 to 2004, and 98 (51%)
centres responded to the questionnaire with 95 of these
providing data that could be used in the analyses. Before
their participation in ADEBAR, 63% of the centres had
not entered high-risk patients into a clinical trial and
44% of patients treated before ADEBAR were judged to
have received inadequate treatment by current stan-
dards. Following their participation in ADEBAR, 80% of
centres reported an improvement in professional knowl-
edge relevant to breast cancer and 31% of centres found
that patient care improved. We judged this study to be
‘poorly controlled’ because it contains insufficient infor-
mation on the control of confounders (such as patient
characteristics), the response rate to the questionnaire
was low and it relies on self-reported data.
Discussion
Taken together, the studies of practitioners and institu-
tions suggest that there might be a ‘trial effect’ of better
outcomes, greater adherence to treatment guidelines and
more use of evidence-based practice in settings that take
part in trials compared to non-trial settings, but these
findings should be treated with caution and require
examination in further, well designed studies (see below).
There is a lack of consistency in the findings across the
studies, with some reporting a statistically significant trial
effects and others reporting no significant differences
between research and non-research settings. This may be
due to a lack of an effect or the lack of sufficient power
to detect a true effect, but the considerable heterogeneity
we encountered means that it was not possible to assess
this through meta-analyses.
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it is possible that the findings are due to bias rather
than a true difference between a research and a non-
research setting. For example, even in studies that we
judged to be ‘controlled’, the absence of randomisation
could mean that important differences between patients
or the treatments they received will have been responsi-
ble for the outcomes, rather than the setting of their
treatment. As others have shown, the correction for
potential confounders in non-randomised studies does
not guarantee that selection biases will be overcome
[19]. Whereas in the ‘poorly controlled’ studies, it is
even more likely that differences between the patients
or their treatments led to at least some of the differ-
ences detected between the settings, as noted above.
Furthermore, we cannot rule out the possibility of
publication or outcome reporting bias, in which either
the availability of the studies we identified was influ-
enced by their findings or the findings that the research-
ers chose to report were influenced by the magnitude of
the effect [20,21]. For example, the majority of studies
did not report on health outcomes and it is possible
that these outcomes were measured, but then not
reported because of their findings. It is not possible to
examine this using, for example, research registers or
accessible protocols because those sources are typically
not available for studies of the type examined in this
review.
Only three of the 13 included studies reported on the
primary outcome for this review, health outcomes for
patients in the different settings. Each of these com-
pared the outcomes for patients treated in trial institu-
tions versus non-trial institutions. The earliest of these
three studies investigated acute myocardial infarction
patients in Canada in the late 1980s and early 1990s,
with a comparison between 40 research hospitals and
165 other hospitals. When patients in the two types of
hospital were compared, after the exclusion of trial par-
ticipants and using multivariable analyses to control for
patient characteristics (age, sex, bypass grafting or cor-
onary angioplasty), hospital mortality was similar
between the trial and the non-trial hospitals [12].
A study from the early 2000s in Germany compared
80 hospitals that took part in clinical trials with
85 other hospitals, finding that deaths following a diag-
nosis of ovarian cancer were more likely in the non-trial
hospitals after adjustment for baseline factors, including
patients characteristics and hospital volume [13]. The
third study, from the USA in the 2000s, compared 123
hospitals with high-trial participation, 226 hospitals with
low trial participation and 145 hospitals with no-trial
participation, finding that patients with non-ST-segment
elevation acute coronary syndrome treated at hospitals
that participated in trials had significantly lower
mortality than patients treated at non-participating hos-
pitals, after adjustment for confounding factors includ-
ing total number of hospital beds, geographic region,
revascularization capabilities, and teaching status of the
hospitals and age, sex, race, insurance status, family his-
tory of coronary disease, medical history, and features of
the initial clinical presentation for the patients [15].
The other studies examined a variety of outcomes
around the care given to patients in the different set-
tings, such as adherence to clinical guidelines or pre-
scription of particular drugs. These process outcomes
might be considered as surrogates for health outcomes,
but without a thorough examination of the potential
effects of the interventions that were reported it is not
possible to conclude whether these were likely to be
beneficial or harmful to the patients in the studies.
Furthermore, if participation in a trial research is more
likely to lead to a practitioner or a hospital using the
findings of that trial, one should be cautious about the
validity of using the results of a single trial, rather than
the systematic review within which it should be placed,
to influence practice [22].
Implications for practice
The limited evidence currently available suggests that
there might be beneficial effects for patients who receive
non-trial treatment from practitioners or in institutions
that take part in trials. The reasons for this difference
are unclear, and the relatively small amount of research
on this subject and the possible influence of confound-
ing by patient characteristics mean that this conclusion
should be viewed with caution and is not robust enough
to influence practice.
Implications for future studies
Among the challenges in interpreting the findings of the
s t u d i e si nt h i sr e v i e wi si d e n t i f y i n gt h ef a c t o r st h a t
might influence differences between patients treated by
trial practitioners or in trial institutions compared to
those treated elsewhere. Future research needs to mini-
mise these differences. The optimal design might be to
randomise patients to be treated in trial versus non-trial
settings, but we realise that this is likely to be difficult
or impossible to implement. We expect that most future
research will continue to use cohort designs. Minimising
the problems of confounding variables will be a key
challenge and these variables include demographic char-
acteristics of patients such as age and sex, and prognos-
tic or clinical characteristics of relevance to the patient’s
underlying condition and likely outcomes. It will also be
important to collect potential explanatory variables for
any differences between trial and non-trial settings. Lar-
ger numbers of patients, practitioners and institutions
should be included in future studies to have sufficient
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larly important if the lack of a significant difference in a
study is to be interpreted as there being truly no impor-
tant difference, rather than a lack of power, in either
direction.
Conclusions
The available findings from existing research suggest
that there might be a ‘trial effect’ of better outcomes,
greater adherence to guidelines and more use of evi-
dence by practitioners and institutions that take part in
trials. However, the magnitude of this effect and the
consequences for patient health are uncertain. The most
robust conclusion may be that there is no apparent evi-
dence that patients treated by practitioners or in institu-
tions that take part in trials do worse than those treated
elsewhere.
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